Skip to main content

Molecular Devices Shares Soar Nearly 50 Percent on MDS Acquisition

 

NEW YORK (GenomeWeb News) - Molecular Devices’ shares surged 47 percent in afternoon trading to $35.05 from Friday’s close of $23.38, in the wake of this morning’s announcement that the company will be bought by MDS.
 
MDS said earlier today that it will pay $615 million in cash for Molecular Devices and combine the firm with its MDS Sciex business.
 
MDS’ stock was up 1.17 percent to $17.30.
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.